Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q4 2025 Earnings Presentation
23 slides from Modus Therapeutics Holding Ab's earnings presentation, Mar 2, 2026
Slide 1: Modus Therapeutics 2025 Year-End Report January-December
MODUS THERAPEUTICS 2025 YEAR-END REPORT JANUARY– DECEMBER 1
Slide 2: Year-End Report in Brief
JANUARY – DECEMBER 2025 YEAR-END REPORT IN BRIEF The fourth quarter in figures • 10 Dec 2025: First patient dosed in Part 2 (PoC) Financial overview • The loss after tax amounted to TSEK 5 320 of Modus’ Phase IIa study in CKD anemia; (4 713). repeat dosing initiated approximately one month 2025 2024
Slide 3: CEO Statement: 2025 – A Year of Execution and Clinical Momentum
CEO STATEMENT 2025 – A YEAR OF EXECUTION AND CLINICAL MOMENTUM 2025 marked an important transition for Modus where our focus moved from preparation and planning to tangible execution and clinical progress. Through successful financing activities during the year, we secured the resources needed to ad
Slide 4: CEO Statement
CEO STATEMENT was completed in the first quarter, representing 2025, and assuming a successful exercise of the collaborators and long-standing network of an important milestone for a program driven outstanding warrants in 2026, we expect to have contracting organizations, as well as the patients pri
Slide 5: About Modus Therapeutics
STATEMENT OF OPERATIONS ABOUT MODUS THERAPEUTICS Modus is developing sevuparin for patients with severe diseases and high unmet medical needs Modus Therapeutics is a Swedish biotechnology company developing sevuparin, an innovative drug candidate with the potential to transform the treatment of dise
Slide 6: Sevuparin – A Drug Candidate with Broad Clinical Potential
STATEMENT OF OPERATIONS SEVUPARIN – A DRUG CANDIDATE WITH BROAD CLINICAL POTENTIAL Modus Therapeutics is developing innovative for higher dosing without increased bleeding tecting the endothelium and neutralizing harmful stands out as an innovative drug candidate treatments for patients suffering fr
Slide 7: Market Overview
STATEMENT OF OPERATIONS MARKET OVERVIEW With sevuparin, Modus is targeting three The market potential is substantial. Modus, Anemia/CKD challenging indications—each with significant together with external analytics firm XPLICO, has standalone potential. identified an addressable market for sevuparin
Slide 8: Statement of Operations: malaria and sepsis indications
STATEMENT OF OPERATIONS adapted mosquito vectors, and climate-related incentives in high-income countries. In the U.S., million deaths globally in 2017—about 20% of all changes that increase the incidence and severity malaria is classified as a rare disease (fewer global deaths that year. In the U.S
Slide 9: Business Model & Collaborations
STATEMENT OF OPERATIONS BUSINESS MODEL & COLLABORATIONS Business model operational and strategic capabilities. According to In non-endemic markets such as the US and EU, Given that sevuparin has the potential to be the first the current development plan, a market launch and malaria/severe malaria ma
Slide 10: Development of Profit and Financial Position
FINANCIAL REPORT DEVELOPMENT OF PROFIT AND FINANCIAL POSITION Fourth quarter Operating profit/loss The operating loss for July–December 2025 amounted to 5 328 (4 846) TSEK. Research and development expenses increased by 515 TSEK versus the same period last year, primarily driven by clinical activiti
Slide 11: Important Events During the Fourth Quarter
FINANCIAL REPORT Important events during the Next steps include site activation and patient screening for Part 2, alongside ongoing business- fourth quarter development activities. Change of Certified Adviser to Bergs Securities AB First patient dosed in Part 2 of Modus On 24 October 2025, Modus ann
Slide 12: Other Disclosures
FINANCIAL REPORT OTHER DISCLOSURES Ownership structure the company generates long term sustainable profit to finance the ongoing Phase IIa study of sevuparin deteriorated investment climate in the capital At the end of the fourth quarter 2025, there were 1 and positive cash flow. in chronic kidney d
Slide 13: Consolidated Summary Income Statement
FINANCIAL REPORT Consolidated summary income statement 2025 2024 2025 2024 TSEK Oct 1–Dec 31 Oct 1–Dec 31 Jan 1–Dec 31 Jan 1–Dec 31 Net sales - - - - Research and development costs -3 368 -2 853 -10 850 -9 067 Administration costs -1 961 -1 978 -7 316 -6 727 Other operating income 1 -15 24 -44 Opera
Slide 14: Consolidated Summary Balance Sheet
FINANCIAL REPORT Consolidated summary balance sheet 2025 2024 TSEK Dec 31 Dec 31 Assets Fixed Assets Other financial fixed assets - 52 Total fixed assets - 52 Current assets Other receivables 1 313 453 Cash equivalents 11 373 4 379 Total current assets 12 686 4 832 TOTAL ASSETS 12 686 4 884 Equity a
Slide 15: Consolidated Change in Shareholder's Equity in Summary
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2025 2024 2025 2024 TSEK Oct 1–Dec 31 Oct 1–Dec 31 Jan 1–Dec 31 Jan 1–Dec 31 Opening balance equity 14 549 6 849 2 137 17 681 Profit/loss for the period -5 320 -4 713 -18 543 -15 545 Total comprehensive income -5 320 -4 713 -18
Slide 16: Consolidated Cash Flow Statement in Summary
FINANCIAL REPORT Consolidated cash flow statement in summary 2025 2024 2025 2024 TSEK Oct 1–Dec 31 Oct 1–Dec 31 Jan 1–Dec 31 Jan 1–Dec 30 Operating activities Operating profit/loss -5 329 -4 846 -18 142 -15 838 Interest received 9 132 9 292 Interest paid 0 0 -1 - Cash flow from operating activities
Slide 17: Parent Company Income Statement in Summary
FINANCIAL REPORT Parent company income statement in summary 2025 2024 2025 2024 TSEK Oct 1–Dec 31 Oct 1–Dec 31 Jan 1–Dec 31 Jan 1–Dec 31 Net sales 185 185 740 740 Research and development costs -390 -365 -1 516 -1 450 Administration costs -1 789 -1 768 -6 706 -6 110 Other operating expenses - - -3 -
Slide 18: Parent Company Balance Sheet
FINANCIAL REPORT Parent company balance sheet 2025 2024 2025 2024 TSEK Dec 31 Dec 31 TSEK Dec 31 Dec 31 Assets Current liabilities Non-current assets Interest-bearing liabilities - - Financial assets 70 000 70 052 Accounts payable 320 144 Total non-current assets 70 000 70 052 Liabilities to Group c
Slide 19: Notes
FINANCIAL REPORT NOTES Note 1. Accounting principles Note 4. Equity Modus Therapeutics Holding AB’s consolidated The share capital of the Parent Company accounts have been prepared in accordance consists only of fully paid ordinary shares with with the annual accounts act and the Swedish a nominal (
Slide 20: Signatures
FINANCIAL REPORT SIGNATURES The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also describes the principal risks and uncertainties faced by the parent
Slide 21: Quarterly Overview
FINANCIAL REPORT QUARTERLY OVERVIEW 2025 2024 2023 The Group Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Definitions Financial key ratio Net sales, TSEK - - - - - - - - - Operating profit Operating profit, TSEK -5 328 -4 226 -5 873 -2 715 -4 846 -2 989 -4 804 -3 199 -3 771 Operating income less operating expenses. E
Slide 22: Leadership Team & Board
LEADERSHIP TEAM & BOARD John Öhd, M.D., PhD Claes Lindblad Viktor Drvota, M.D, PhD Johan Dighed Ellen K. Donnelly, PhD CEO since 2020 and previously CMO since CFO since 2021. Chairman since 2016. Board Member since September 2024. Board Member since 2020. 2018. Born: 1967 Born: 1965 Born: 1973 Born:
Slide 23: Contact
Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden +46 (0)8-501 370 00 info@modustx.com www.modustx.com Contact John Öhd, CEO +46 (0)70-744 80 97 john.ohd@modustx.com Claes Lindblad, CFO & Head of IR +46 (0)70-246 75 54 claes.lindblad@modustx.com 23
Modus Therapeutics Holding — Q4 2025 Earnings Presentation on 6ix